Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases (OMESIA)

Hunan Province Tumor Hospital

Status: Completed

Conditions: Non Small Cell Lung Cancer

Treatments: Drug: immune therapy

Study type: Observational

Funder types: Other

Identifiers

NCT05129202

OMESIA

Details and patient eligibility

About

Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis 3. Treated with ICIs

Exclusion criteria

• 1.Patients with a clear driver mutation that can be targeted for first-line treatment

Trial design

200 participants in 2 patient groups

Chemotherapy alone or chemotherapy combined with anti-angiogenesis

Description:

patients with Chemotherapy

immuntherapy

Description:

patients treated with immune checkpoint inhibitor monotherapy or combination therapy.

Treatment:

Drug: immune therapy